Literature DB >> 10591184

Interaction of the NK cell inhibitory receptor Ly49A with H-2Dd: identification of a site distinct from the TCR site.

K Natarajan1, L F Boyd, P Schuck, W M Yokoyama, D Eliat, D H Margulies.   

Abstract

Natural killer cell function is controlled by interaction of NK receptors with MHC I molecules expressed on target cells. We describe the binding of bacterially expressed Ly49A, the prototype murine NK inhibitory receptor, to similarly engineered H-2Dd. Despite its homology to C-type lectins, Ly49A binds independently of carbohydrate and Ca2+ and shows specificity for MHC I but not bound peptide. The affinity of the Ly49A/H-2Dd interaction as determined by surface plasmon resonance is from 6 to 26 microM at 25 degrees C and is greater by ultracentrifugation at 4 degrees C. Biotinylated Ly49A stains H-2Dd-expressing cells. Competition experiments indicate that the Ly49A and T cell receptor (TCR) binding sites on MHC I are distinct, suggesting complex regulation of cells that bear both TCR and NK cell receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591184     DOI: 10.1016/s1074-7613(00)80134-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  14 in total

1.  Combined affinity and rate constant distributions of ligand populations from experimental surface binding kinetics and equilibria.

Authors:  Juraj Svitel; Andrea Balbo; Roy A Mariuzza; Noreen R Gonzales; Peter Schuck
Journal:  Biophys J       Date:  2003-06       Impact factor: 4.033

2.  Activation or tolerance of natural killer cells is modulated by ligand quality in a nonmonotonic manner.

Authors:  Jayajit Das
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

3.  Essential role of the Ly49A stalk region for immunological synapse formation and signaling.

Authors:  Daisuke Ito; Yoshie-Matsubayashi Iizuka; Madhu P Katepalli; Koho Iizuka
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

Review 4.  The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions.

Authors:  Subramaniam Malarkannan
Journal:  Semin Immunol       Date:  2006-06       Impact factor: 11.130

5.  A Novel MHC-I Surface Targeted for Binding by the MCMV m06 Immunoevasin Revealed by Solution NMR.

Authors:  Nikolaos G Sgourakis; Nathan A May; Lisa F Boyd; Jinfa Ying; Ad Bax; David H Margulies
Journal:  J Biol Chem       Date:  2015-10-13       Impact factor: 5.157

6.  Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.

Authors:  Daniel M Andrews; Lucy C Sullivan; Nikola Baschuk; Christopher J Chan; Richard Berry; Claire L Cotterell; Jie Lin; Heloise Halse; Sally V Watt; Jennifer Poursine-Laurent; Chyung-Ru Wang; Anthony A Scalzo; Wayne M Yokoyama; Jamie Rossjohn; Andrew G Brooks; Mark J Smyth
Journal:  Nat Immunol       Date:  2012-11-11       Impact factor: 25.606

7.  The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands.

Authors:  Brian J Ma; Carla M Craveiro Salvado; Kevin P Kane
Journal:  Immunogenetics       Date:  2014-05-07       Impact factor: 2.846

8.  Cutting Edge: Inhibition of the Interaction of NK Inhibitory Receptors with MHC Class I Augments Antiviral and Antitumor Immunity.

Authors:  Abir K Panda; Arunakumar Gangaplara; Maja Buszko; Kannan Natarajan; Lisa F Boyd; Suveena Sharma; David H Margulies; Ethan M Shevach
Journal:  J Immunol       Date:  2020-06-29       Impact factor: 5.422

9.  Recognition of class I MHC by a rat Ly49 NK cell receptor is dependent on the identity of the P2 anchor amino acid of bound peptide.

Authors:  Brian J Ma; Kevin P Kane
Journal:  J Immunol       Date:  2011-08-12       Impact factor: 5.422

Review 10.  How the virus outsmarts the host: function and structure of cytomegalovirus MHC-I-like molecules in the evasion of natural killer cell surveillance.

Authors:  Maria Jamela Revilleza; Rui Wang; Janet Mans; Manqing Hong; Kannan Natarajan; David H Margulies
Journal:  J Biomed Biotechnol       Date:  2011-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.